Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 16;14:17562864211001995. doi: 10.1177/17562864211001995

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2021

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 3. — (a) MG-ADL responders^a and (b) QMG responders^b after 12 and 26 weeks of eculizumab treatment in all patients with generalized myasthenia gravis and in subgroups of patients with and without a history of thymoma (effectiveness analysis set).

^a⩾3-point improvement in MG-ADL total score after eculizumab initiation.

^b⩾5-point improvement in QMG total score after eculizumab initiation.

MG-ADL, Myasthenia Gravis Activities of Daily Living score; QMG, Quantitative Myasthenia Gravis score.